Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
LivaNova is a medical device company focused on two core franchises: Cardiovascular (heart-lung machines, oxygenators, cardioplegia delivery systems) and Neuromodulation (vagus nerve stimulation therapy for drug-resistant epilepsy and treatment-resistant depression). The company operates globally with manufacturing in Italy, Germany, and the US, serving hospitals and specialized neurologists. Stock performance is driven by Neuromodulation adoption rates, cardiac surgery procedure volumes, and new product approvals.
LivaNova generates revenue through capital equipment sales (heart-lung machines, neuromodulation implants) and high-margin recurring disposables/consumables. Cardiovascular business benefits from installed base of perfusion systems requiring proprietary disposables for each cardiac surgery. Neuromodulation creates annuity-like revenue as implanted devices require replacement batteries every 5-8 years, with ~50,000 active patients globally. Pricing power stems from regulatory barriers (FDA/CE Mark approvals take 3-5 years), surgeon training requirements, and switching costs in hospital capital equipment. Gross margins of 69.5% reflect mix of capital equipment (50-55% margins) and disposables (75-80% margins).
Neuromodulation implant volumes and market penetration in treatment-resistant depression (TRD) indication, currently <5% penetrated market
Cardiac surgery procedure volumes globally, particularly in Europe (40% of revenue) and US (35% of revenue), which correlate with elective surgery rates
New product launches: Advanced Connect 3D heart-lung machine adoption, next-generation VNS devices with extended battery life
Reimbursement decisions for VNS Therapy in depression from CMS and European payers, critical for TRD market expansion
Margin expansion initiatives in Cardiovascular segment through manufacturing consolidation and product mix shift to premium disposables
Regulatory pathway uncertainty for expanded VNS Therapy indications (obesity, heart failure) requiring multi-year clinical trials and FDA approvals with binary outcomes
Reimbursement pressure from government payers (Medicare, European health systems) seeking to reduce device costs, particularly for capital equipment where hospitals negotiate volume discounts
Technological disruption risk in Neuromodulation from competing modalities (responsive neurostimulation, deep brain stimulation) or pharmaceutical advances in epilepsy treatment
Cardiovascular segment faces competition from Getinge, Medtronic, and Terumo in perfusion systems with limited product differentiation beyond installed base advantages
Neuromodulation competes with Medtronic (deep brain stimulation), NeuroPace (responsive neurostimulation), and emerging closed-loop systems offering superior seizure detection
Pricing pressure in mature European markets where government tenders favor lowest-cost suppliers, compressing Cardiovascular margins
Negative ROE of -18.8% and ROA of -14.2% indicate accumulated losses or goodwill impairments from past acquisitions, requiring monitoring of asset quality
Free cash flow of $0.1B on $1.3B revenue (7.7% FCF margin) is below med-tech peer average of 15-20%, limiting financial flexibility for R&D or M&A
Currency exposure with 40% of revenue in Europe creates earnings volatility from EUR/USD fluctuations (10% FX move impacts EPS by ~5-7%)
moderate - Cardiovascular segment (65-70% of revenue) is tied to elective cardiac surgery volumes, which decline 10-15% during recessions as hospitals defer non-emergency procedures and patients delay treatment. Neuromodulation segment is more defensive as epilepsy treatment is non-discretionary, though depression indication adoption may slow with reduced healthcare spending. Hospital capital equipment budgets are pro-cyclical, affecting heart-lung machine sales. Overall revenue correlation to GDP growth is ~0.6x given mix of elective and essential procedures.
Rising rates have modest negative impact through two channels: (1) Hospital capital budgets tighten as borrowing costs increase, potentially delaying heart-lung machine purchases (15-20% of Cardiovascular revenue); (2) Higher discount rates compress valuation multiples for med-tech growth stocks. However, limited direct debt refinancing risk given moderate 0.42 Debt/Equity ratio. Company benefits from floating-rate assets (cash) exceeding floating-rate liabilities. Net impact: mildly negative on valuation, minimal on operations.
Minimal direct credit exposure. Customer base is hospitals and healthcare systems with stable payment histories. No significant accounts receivable concentration risk. Company maintains investment-grade credit profile with ability to access capital markets for M&A or R&D investments. Tightening credit conditions could indirectly reduce hospital capital spending budgets.
growth - Investors focus on Neuromodulation segment's expansion potential in underpenetrated TRD market (estimated $3B+ opportunity) and international Cardiovascular growth in emerging markets. Recent 42.4% one-year return and 260% net income growth attract momentum investors, though growth is from low base following restructuring. Valuation at 2.7x Price/Sales is premium to diversified med-tech (2.0x average) but below pure-play neuromodulation peers (3.5-4.0x), appealing to GARP investors seeking recovery stories with operating leverage.
moderate-high - Beta estimated at 1.1-1.3x based on 42% one-year return versus S&P 500. Volatility driven by binary clinical trial outcomes, quarterly revenue beats/misses in small Neuromodulation segment, and FX swings. Smaller $3.7B market cap increases susceptibility to institutional flow volatility. Recent 25.5% three-month return suggests elevated momentum-driven trading.
